Roles and resistance mechanisms of survivin in tumor

doi:10.3760/cma.j.issn.1673-422X.2014.04.001

Abstract

ZHENG Ying, CHEN Qin, ZHANG Bin, CAO Xu-Chen. Roles and resistance mechanisms of survivin in tumor[J]. Journal of International Oncology, 2014, 41(4): 241-243.

［1］ Salvesen GS, Duckett CS. IAP proteins: blocking the road to death′s door［J］. Nat Rev Mol Cell Biol, 2002, 3(6): 401410. ［2］ Verdecia MA, Huang H, Dutil E, et al. Structure of the human antiapoptotic protein survivin reveals a dimeric arrangement［J］. Nat Struct Biol, 2000, 7(7): 602608. ［3］ Li F, Ackermann EJ, Bennett CF, et al. Pleiotropic celldivision defects and apoptosis induced by interference with survivin function［J］. Nat Cell Biol, 1999, 1(8): 461466. ［4］ Wang L, Yin F, Du Y, et al. Depression of MAD2 inhibits apoptosis and increases proliferation and multidrug resistance in gastric cancer cells by regulating the activation of phosphorylated survivin［J］. Tumour Biol, 2010, 31(3): 225232. ［5］ Wang P, Zhen H, Zhang J, et al. Survivin promotes glioma angiogenesis through vascular endothelial growth factor and basic fibroblast growth factor in vitro and in vivo［J］. Mol Carcinog, 2012, 51(7): 586595. ［6］ Li Z, Yang S, Chang T, et al. Antiangiogenesis and anticancer effects of a plasmid expressing both ENDOVEGI151 and small interfering RNA against survivin［J］. Int J Mol Med, 2012, 29(3): 485490. ［7］ Lee J, Choi JH, Joo CK. TGFβ1 regulates cell fate during epithelialmesenchymal transition by upregulating survivin［J］. Cell Death Dis, 2013, 4: e714. ［8］ Ye Q, Cai W, Zheng Y, et al. ERK and AKT signaling cooperate to translationally regulate survivin expression for metastatic progression of colorectal cancer［J］. Oncogene, 2013, In press. ［9］ Sos ML, Koker M, Weir BA, et al. PTEN loss contributes to erlotinib resistance in EGFRmutant lung cancer by activation of Akt and EGFR［J］. Cancer Res, 2009, 69(8): 32563261. ［10］ Yamamoto C, Basaki Y, Kawahara A, et al. Loss of PTEN expression by blocking nuclear translocation of EGR1 in gefitinibresistant lung cancer cells harboring epidermal growth factor receptoractivating mutations［J］. Cancer Res, 2010, 70(21): 87158725. ［11］ Okamoto K, Okamoto I, Okamoto W, et al. Role of survivin in EGFR inhibitorinduced apoptosis in nonsmall cell lung cancers positive for EGFR mutations［J］. Cancer Res, 2010, 70(24): 1040210410. ［12］ Okamoto K, Okamoto I, Hatashita E, et al. Overcoming erlotinib resistance in EGFR mutationpositive nonsmall cell lung cancer cells by targeting survivin［J］. Mol Cancer Ther, 2012, 11(1): 204213. ［13］ Guha M, Plescia J, Leav I, et al. Endogenous tumor suppression mediated by PTEN involves survivin gene silencing［J］. Cancer Res, 2009, 69(12): 49544958. ［14］ Fletcher JI, Haber M, Henderson MJ, et al. ABC transporters in cancer: more than just drug efflux pumps［J］. Nat Rev Cancer, 2010, 10(2): 147156. ［15］ Tsubaki M, Satou T, Itoh T, et al. Overexpression of MDR1 and survivin, and decreased Bim expression mediate multidrugresistance in multiple myeloma cells［J］. Leuk Res, 2012, 36(10): 13151322. ［16］ Guenova ML, Balatzenko GN, Nikolova VR, et al. An antiapoptotic pattern correlates with multidrug resistance in acute myeloid leukemia patients: a comparative study of active caspase3, cleaved PARPs, Bcl2, Survivin and MDR1 gene［J］. Hematology, 2010, 15(3): 135143. ［17］ He Q, Gao Y, Zhang L, et al. A pHresponsive mesoporous silica nanoparticlesbased multidrug delivery system for overcoming multidrug resistance［J］. Biomaterials, 2011, 32(30): 77117720. ［18］ Cho HJ, Yoon HY, Koo H, et al. Selfassembled nanoparticles based on hyaluronic acidceramide (HACE) and Pluronic(R) for tumortargeted delivery of docetaxel［J］. Biomaterials, 2011, 32(29): 71817190. ［19］ Vergara D, Bellomo C, Zhang X, et al. Lapatinib/Paclitaxel polyelectrolyte nanocapsules for overcoming multidrug resistance in ovarian cancer［J］. Nanomedicine, 2012, 8(6): 891899. ［20］ Liu F, Liu S, He S, et al. Survivin transcription is associated with Pglycoprotein/MDR1 overexpression in the multidrug resistance of MCF7 breast cancer cells［J］. Oncol Rep, 2010, 23(5): 14691475. ［21］ Bhattacharyya J, Mihara K, Ohtsubo M, et al. Overexpression of BMI1 correlates with drug resistance in Bcell lymphoma cells through the stabilization of survivin expression［J］. Cancer Sci, 2012, 103(1): 3441. ［22］ OliverasFerraros C, VazquezMartin A, Cufi S, et al. Inhibitor of Apoptosis (IAP) survivin is indispensable for survival of HER2 geneamplified breast cancer cells with primary resistance to HER1/2targeted therapies［J］. Biochem Biophys Res Commun, 2011, 407(2): 412419. ［23］ Zhu H, Zhang G, Wang Y, et al. Inhibition of ErbB2 by Herceptin reduces survivin expression via the ErbB2betacatenin/TCF4survivin pathway in ErbB2overexpressed breast cancer cells［J］. Cancer Sci, 2010, 101(5): 11561162. ［24］ Foster FM, Owens TW, TanianisHughes J, et al. Targeting inhibitor of apoptosis proteins in combination with ErbB antagonists in breast cancer［J］. Breast Cancer Res, 2009, 11(3): R41. ［25］ Wang S, Huang X, Lee CK, et al. Elevated expression of erbB3 confers paclitaxel resistance in erbB2overexpressing breast cancer cells via upregulation of Survivin［J］. Oncogene, 2010, 29(29): 42254236. ［26］ Kelly RJ, Thomas A, Rajan A, et al. A phase Ⅰ/Ⅱ study of sepantronium bromide (YM155, survivin suppressor) with paclitaxel and carboplatin in patients with advanced nonsmallcell lung cancer［J］. Ann Oncol, 2013, 24(10): 2601-2606.

[1]	Liu Na, Kou Jieli, Yang Feng, Liu Taotao, Li Danping, Han Junrui, Yang Lizhou. Clinical value of serum miR-106b-5p and miR-760 combined with low-dose spiral CT in the diagnosis of early lung cancer [J]. Journal of International Oncology, 2024, 51(6): 321-325.
[2]	Yang Mi, Bie Jun, Zhang Jiayong, Deng Jiaxiu, Tang Zuge, Lu Jun. Analysis of the efficacy and prognosis of neoadjuvant therapy for locally advanced resectable esophageal cancer [J]. Journal of International Oncology, 2024, 51(6): 332-337.
[3]	Yuan Jian, Huang Yanhua. Diagnostic value of Hp-IgG antibody combined with serum DKK1 and sB7-H3 in early gastric cancer [J]. Journal of International Oncology, 2024, 51(6): 338-343.
[4]	Chen Hongjian, Zhang Suqing. Study on the relationship between serum miR-24-3p， H2AFX and clinical pathological features and postoperative recurrence in liver cancer patients [J]. Journal of International Oncology, 2024, 51(6): 344-349.
[5]	Guo Zehao, Zhang Junwang. Role of PFDN and its subunits in tumorigenesis and tumor development [J]. Journal of International Oncology, 2024, 51(6): 350-353.
[6]	Zhang Baihong, Yue Hongyun. Advances in anti-tumor drugs with new mechanisms of action [J]. Journal of International Oncology, 2024, 51(6): 354-358.
[7]	Xu Fenglin, Wu Gang. Research progress of EBV in tumor immune microenvironment and immunotherapy of nasopharyngeal carcinoma [J]. Journal of International Oncology, 2024, 51(6): 359-363.
[8]	Wang Ying, Liu Nan, Guo Bing. Advances of antibody-drug conjugate in the therapy of metastatic breast cancer [J]. Journal of International Oncology, 2024, 51(6): 364-369.
[9]	Zhang Rui, Chu Yanliu. Research progress of colorectal cancer risk assessment models based on FIT and gut microbiota [J]. Journal of International Oncology, 2024, 51(6): 370-375.
[10]	Gao Fan, Wang Ping, Du Chao, Chu Yanliu. Research progress on intestinal flora and non-surgical treatment of the colorectal cancer [J]. Journal of International Oncology, 2024, 51(6): 376-381.
[11]	Liu Jing, Liu Qin, Huang Mei. Prognostic model construction of lung infection in patients with chemoradiotherapy for esophageal cancer based on SMOTE algorithm [J]. Journal of International Oncology, 2024, 51(5): 267-273.
[12]	Yang Lin, Lu Ning, Wen Hua, Zhang Mingxin, Zhu Lin. Study on the clinical relationship between inflammatory burden index and gastric cancer [J]. Journal of International Oncology, 2024, 51(5): 274-279.
[13]	Wang Junyi, Hong Kaibin, Ji Rongjia, Chen Dachao. Effect of cancer nodules on liver metastases after radical resection of colorectal cancer [J]. Journal of International Oncology, 2024, 51(5): 280-285.
[14]	Zhang Ningning, Yang Zhe, Tan Limei, Li Zhenning, Wang Di, Wei Yongzhi. Diagnostic value of cervical cell DNA ploidy analysis combined with B7-H4 and PKCδ for cervical cancer [J]. Journal of International Oncology, 2024, 51(5): 286-291.
[15]	Fu Yi, Ma Chenying, Zhang Lu, Zhou Juying. Research progress of habitat analysis in radiomics of malignant tumors [J]. Journal of International Oncology, 2024, 51(5): 292-297.

Roles and resistance mechanisms of survivin in tumor

PDF

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments